2014
High risk and rapid appearance of multidrug resistance during tuberculosis treatment in Moldova.
Jenkins HE, Crudu V, Soltan V, Ciobanu A, Domente L, Cohen T. High risk and rapid appearance of multidrug resistance during tuberculosis treatment in Moldova. European Respiratory Journal 2014, 43: 1132-41. PMID: 24558181, PMCID: PMC4005038, DOI: 10.1183/09031936.00203613.Peer-Reviewed Original ResearchConceptsMultidrug-resistant tuberculosisMDR-TB diagnosisMDR-TB casesTB treatmentFirst-line TB drugsAmbulatory TB treatmentMDR-TB riskDrug susceptibility testingNosocomial transmissionInitial diagnosisPercentage of individualsTB drugsTuberculosis treatmentEarly treatmentHigh riskSputum specimensSurveillance databasePrevious incarcerationDrug resistanceMultidrug resistanceDiagnosisTreatmentBaseline resistanceRapid appearanceRisk
2012
Population Health Impact and Cost-Effectiveness of Tuberculosis Diagnosis with Xpert MTB/RIF: A Dynamic Simulation and Economic Evaluation
Menzies NA, Cohen T, Lin HH, Murray M, Salomon JA. Population Health Impact and Cost-Effectiveness of Tuberculosis Diagnosis with Xpert MTB/RIF: A Dynamic Simulation and Economic Evaluation. PLOS Medicine 2012, 9: e1001347. PMID: 23185139, PMCID: PMC3502465, DOI: 10.1371/journal.pmed.1001347.Peer-Reviewed Original ResearchConceptsMultidrug-resistant TBCost-effectiveness ratioInitial diagnosisXpert MTB/RIF testMTB/RIF testXpert MTB/RIFIntroduction of XpertTB natural historyTB-HIV coinfectionMultidrug-resistant tuberculosisHigh HIV prevalenceMTB/RIFHealth system costsImplementation of XpertHealth impactsPopulation health impactCost-effectiveness resultsLong-term transmission dynamicsWorld Health OrganizationAntiretroviral therapyTB casesTB deathsTB morbidityHIV prevalenceRIF test